Arterial Stiffness and Stroke in Sickle Cell Disease

Cristina Belizna(Inserm), Norbert Ifrah(Institut National du Cancer), Agnès Lahary(Inserm), J Louvel(Inserm), E. Primard(Inserm), Laurent Loufrani(Centre National de la Recherche Scientifique), Daniel Henrion(Université d'Angers), H. Lévesque(Centre Hospitalier Universitaire de Rouen), A. Ghali(Laboratoires d'Anjou (France))
Stroke
December 24, 2011
10.1161/strokeaha.111.635383
Cited by 25

Related Papers

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
|Blood|2013|357
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
|Blood|2013|286
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
|Blood|2007|252
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
|Blood|2010|196
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
|Leukemia|2008|193